A
Agilent Technologies, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$150.98
+0.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.4B | 6.9B | 6.5B | 6.8B | 6.8B |
| Cost of Revenue | 3.4B | 3.3B | 3.0B | 3.4B | 3.1B |
| Gross Profit | 4.0B | 3.6B | 3.5B | 3.5B | 3.7B |
| Operating Expenses | |||||
| R&D Expense | 485.0M | 455.0M | 479.0M | 481.0M | 467.0M |
| SG&A Expense | 1.8B | 1.7B | 1.5B | 1.6B | 1.6B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (7.0M) | — | 50.0M | — | — |
| Total Operating Expenses | 2.3B | 2.2B | 2.0B | 2.1B | 2.1B |
| Cost and Expenses | 5.7B | 5.5B | 5.0B | 5.5B | 5.2B |
| Operating Income (EBIT) | 1.6B | 1.5B | 1.5B | 1.4B | 1.6B |
| Non-Operating | |||||
| Interest Income | 60.0M | 62.0M | 80.0M | 51.0M | 9.0M |
| Interest Expense | 106.0M | 112.0M | 96.0M | 95.0M | 84.0M |
| Net Interest Income | (46.0M) | (50.0M) | (16.0M) | (44.0M) | (75.0M) |
| Other Non-Op Income/Expense | 19.0M | (44.0M) | 33.0M | (11.0M) | (114.0M) |
| Non-Operating Income (excl Interest) | (125.0M) | (68.0M) | (129.0M) | (84.0M) | 30.0M |
| EBT (Pre-Tax Income) | 1.7B | 1.4B | 1.5B | 1.3B | 1.5B |
| Income Tax Expense | 218.0M | 132.0M | 232.0M | 99.0M | 250.0M |
| Bottom Line | |||||
| Net Income | 1.4B | 1.3B | 1.3B | 1.2B | 1.3B |
| Earnings from Cont. Ops | 1.4B | 1.3B | 1.3B | 1.2B | 1.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.4B | 1.3B | 1.3B | 1.2B | 1.3B |
| Per Share | |||||
| Basic EPS | $5.09 | $4.59 | $4.44 | $4.22 | $4.19 |
| Diluted EPS | $5.08 | $4.57 | $4.43 | $4.19 | $4.18 |
| Revenue Per Share | $26.14 | $24.55 | $22.45 | $23.24 | $22.90 |
| Shares | |||||
| Basic Shares Outstanding | 282.0M | 283.0M | 290.0M | 294.0M | 299.0M |
| Diluted Shares Outstanding | 283.0M | 284.0M | 291.0M | 296.0M | 300.0M |
| Profitability Metrics | |||||
| EBITDA | 2.0B | 1.8B | 1.9B | 1.7B | 1.9B |
| D&A | 205.0M | 288.0M | 257.0M | 271.0M | 317.0M |
| EBIT | 1.8B | 1.5B | 1.6B | 1.4B | 1.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026